# A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S

> **NIH NIH N01** · JOHNS HOPKINS UNIVERSITY · 2024 · $321,765

## Abstract

To support a phase two clinical trial to evaluate a dengue vaccine candidate.

## Key facts

- **NIH application ID:** 11076168
- **Project number:** 75N93019D00031-P00001-759302300004-1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Anna Palmer Durbin
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $321,765
- **Award type:** —
- **Project period:** 2023-08-23 → 2025-07-22

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11076168

## Citation

> US National Institutes of Health, RePORTER application 11076168, A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S (75N93019D00031-P00001-759302300004-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11076168. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*